STUDY NUMBER: 2600398

Dear pioneer,

A study to the **treatment of cardiovascular and kidney diseases** will soon start at our research centre in Edegem.
Are you interested in participating and giving science a boost?
Hereby we would like to give you an overview of the study: duration of **± 8 weeks**.

In this panel, the study medication will be administered **orally** (by mouth).

INCLUSION CRITERIA

- **Last participation in other clinical study (final study visit):**
  Panel E: no later than **24NOV2026** (4 weeks before the screening visit)
  **Be careful: Final study visit of the previous study needs to be performed to be able to participate at screening.*
- Healthy males and infertile females aged 18 to 55 years (inclusive)
- BMI: between 18 and 32 kg/m² (inclusive)
- Non-smoker or have stopped smoking for at least 3 months before screening (including nicotine-containing products such as nicotine patches or electronic cigarettes)
- No use of medication, vitamins, or homeopathic products
- Contraception:
  - **Infertile females**
    - Postmenopausal (no menstruation for at least 12 months)
    - **OR** undergone removal of the uterus
    - **OR** undergone removal of both ovaries
    - **OR** undergone removal of both fallopian tubes
    - **OR** another medical reason
  - **Men**: (from the first administration of study medication until 4 days after the last administration of study medication)
    - Use of a condom:
      - if the female partner is of childbearing potential
      - if the female partner is pregnant or breastfeeding
    - Sterilization
- You will be asked to comply with restrictions regarding physical activity, consumption of grapefruit and grapefruit juice products, caffeine-containing products and alcohol-containing products
- No previous participation in any of the preceding panels of this study
- You not an employee or family member of an employee of SGS or the sponsor, Merck Sharp & Dohme LLC (MSD)

- **You are not eligible if you:**
  - Have a history of Hepatitis C, Tuberculosis and/or HIV, or have an active Hepatitis B infection
  - Have undergone or have planned major surgery, or have donated or lost blood (approximately 500 mL) within 4 weeks prior to screening
  - Have a severe allergy (e.g., to medication, latex, or certain foods). If in doubt, this can be discussed with the physician during screening.
  - Have a history of malignancies
  - Have an infection (e.g., a cold) at the time of screening or dosing
  - of Asian origin

INTEREST IN PARTICIPATING

Registration for this study only indicates your interest and does not obligate you to participate, nor us to include you as a participant.

Thank you in advance for your interest and we hope to welcome you soon for study 2600398.

SGS CPU